Silence Therapeutics plc

Regulatory Filings • Apr 28, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6028F

Silence Therapeutics PLC

28 April 2014

SILENCE THERAPEUTICS PLC

Gene knockdown in non-human primates

28 April 2014

Silence Therapeutics is pleased to announce that it has successfully shown gene knockdown in non-human primates using its RNA lung delivery system, DACC. This confirms that Silence Therapeutics has a broad delivery capability in RNA Therapeutics with validated delivery systems in the lung and the vasculature in vitro, in rodents and in non-human primates. The company's systemic vasculature delivery system, AtuPlex, is also currently being used in human clinical trials with an excellent safety profile.

Silence's Chief Executive Officer Ali Mortazavi said:

"The translation of our rodent data in DACC to non-human primates is a significant milestone. We have a broad and diversified technology platform from which to capitalise on our promise of becoming a product company. The ability to deliver RNA payloads to multiple tissues gives us a wide variety of choice from which to build a drug pipeline."

For further information please contact:

Silence Therapeutics	Canaccord Genuity Limited
Ali Mortazavi, Chief Executive	Lucy Tilley
Annie Cheng, Chief Operating Officer	Dr Julian Feneley
Timothy Freeborn, Finance Director	Henry Fitzgerald-O'Connor
+44 (0) 20 3700 9711	+44 (0) 207 523 8350

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBCGDSLSDBGSR